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Abstract
Malignant cancers that lead to fatal outcomes for patients may remain dormant for very long periods of time. Although
individual mechanisms such as cellular dormancy, angiogenic dormancy and immunosurveillance have been proposed, a
comprehensive understanding of cancer dormancy and the ‘‘switch’’ from a dormant to a proliferative state still needs to be
strengthened from both a basic and clinical point of view. Computational modeling enables one to explore a variety of
scenarios for possible but realistic microscopic dormancy mechanisms and their predicted outcomes. The aim of this paper
is to devise such a predictive computational model of dormancy with an emergent ‘‘switch’’ behavior. Specifically, we
generalize a previous cellular automaton (CA) model for proliferative growth of solid tumor that now incorporates a variety
of cell-level tumor-host interactions and different mechanisms for tumor dormancy, for example the effects of the immune
system. Our new CA rules induce a natural ‘‘competition’’ between the tumor and tumor suppression factors in the
microenvironment. This competition either results in a ‘‘stalemate’’ for a period of time in which the tumor either eventually
wins (spontaneously emerges) or is eradicated; or it leads to a situation in which the tumor is eradicated before such a
‘‘stalemate’’ could ever develop. We also predict that if the number of actively dividing cells within the proliferative rim of
the tumor reaches a critical, yet low level, the dormant tumor has a high probability to resume rapid growth. Our findings
may shed light on the fundamental understanding of cancer dormancy.
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Introduction
Cancer dormancy, the phenomena that the tumor’s volume or
the number of tumor cells stays at a very low level for a certain
period of time before the tumor begins to grow rapidly, has been
an outstanding issue in cancer research for many years [1,2].
Currently, the mechanisms responsible for the ‘‘switch’’ from a
dormant state to a rapid growth state for different tumors are not
well understood, although it is well known that such a ‘‘switch’’ in
secondary metastatic tumors can be triggered by the removal of
the primary tumor. This could eventually lead to failure of tumor
treatment and fatal outcomes for the patient. Therefore, a
comprehensive understanding of the ‘‘switch’’ from a dormant
to a proliferative state is crucial to our fundamental understanding
of cancer progression and recurrence and might lead to the
development of novel treatments for cancer.
Dormancy has been observed in many types of cancer. This
includes tumor dormancy before any metastases take place and the
latency of cancer recurrence after therapy. In some cases of
pancreatic cancer, the tumor can remain in a benign dormant
state for about 20 years [3]. During this time, it is undetectable by
conventional clinical methods, and it is only afterwards that the
tumor becomes highly malignant and grows aggressively with
highly fatal outcomes after about a year. In the cases of breast and
prostate cancer, it is reported that 20%–45% of patients will
relapse years or decades later after the resection of the primary
tumor [4–6]. In addition, recurrence has been observed in brain
tumors, which indicates the existence of a large number of
micrometastases that are dormant in the presence of the primary
tumor [7,8].
Extensive studies over years have revealed three major cancer
dormancy mechanisms: cellular dormancy, angiogenic dormancy
and immunosurveillance [1,2]. On the cellular level, a tumor cell
could be arrested at a certain stage of the cell cycle and unable to
complete the cell division process successfully, resulting in a
dormant solitary cell [9–11]. On the cell population level, when
the population does not gain enough ability to recruit blood vessels
and promote neovascularization, the tumor cannot obtain
sufficient nutrients necessary for its proliferation and as a result,
angiogenic dormancy occurs [12,13]. On other hand, immuno-
surveillance operates when the immune system suppresses the
proliferation of tumor cell population and leads to the dormancy
of the tumor [14–18]. Figure 1(a) shows an image of tumor tissue
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surrounded by immune cells. Figure 1(b) compares the morphol-
ogy and vascular structure of dormant and fast-growing tumors.
A comprehensive understanding of cancer dormancy and the
‘‘switch’’ from a dormant to a proliferative state still needs to be
strengthened. This is mainly due to the fact that efficient and
accurate experimental or clinical approaches to track the states of
individual cells in a dormant tumor in vivo throughout the entire
dormancy period are still under development [19–21].
Given the current need for further understanding of dormancy,
computational modeling provides a powerful means to probe
various scenarios for the underlying mechanisms. Specifically,
modeling enables one to probe a variety of different dormancy
scenarios by examining different combinations of mechanisms in
order to see which ones provide possible explanations for
experimental and clinical observations. Over the past few decades,
computational modeling has played an important role in the study
of the progression of solid tumors [22]; a variety of models based
on different mathematical schemes have been developed, includ-
ing continuum models [23–26], discrete cell models [27,28] and
hybrid models [29,30]. Various models have been used to
investigate cancer dormancy caused by cancer-immune interac-
tions and other mechanisms, including ordinary differential
equation-based models [31,32], stochastic differential equation-
based models [33], models based on kinetic theory for active
particles [34–36], and cellular automaton models [37]. However,
the aforementioned studies neither explicitly demonstrated how
the dynamic process of active proliferation after a certain period of
dormancy emerges from various microscopic mechanisms nor
showed the associated growth dynamics of the ‘‘switch’’ phenom-
enon. Therefore, predictive computational models that incorpo-
rate cellular-level microscopic mechanisms are needed to address
these important issues.
In this paper, we generalize a two-dimensional (2D) cellular
automaton (CA) model that we have devised to study proliferative
growth of avascular solid tumors [38–42] in order to investigate
tumor dormancy. Our goal is to formulate a dynamical model in
which the ‘‘switch’’ to a proliferative state spontaneously emerges
by incorporating additional interactions between the tumor and
the microenvironment, for example the effects of immune system,
which were not included in our previous CA model. The new rules
of our CA model induce a ‘‘competition’’ between the tumor’s
propensity to proliferate and the microenvironmental factors that
suppress its growth. In our model, a fraction of the dormant cells
undergo phenotypic transformations triggered by intracellular
factors or external stimulus and acquire the ability to actively
proliferate. Subsequently, those microenvironmental factors act to
suppress the growth of these transformed tumor cells either by
killing some of these cells or turning these actively dividing
proliferative cells back into dormant cells.
The ‘‘competition’’ between the tumor and the microenviron-
mental suppression factors either results in a ‘‘stalemate’’ for a
period of time in which the tumor either eventually wins
(spontaneously emerges) or is eradicated; or it leads to a situation
in which the tumor is eradicated before such a ‘‘stalemate’’ could
ever develop. Since we are mainly interested in the situations in
which tumor growth involves a period of dormancy, we will
henceforth focus on those situations in which a ‘‘stalemate’’
between the tumor and the microenvironmental suppression
factors develops. Our model demonstrates that a variety of
parameters characterizing the tumor-host interactions may greatly
alter the growth dynamics of the tumor. These parameters include
the rate of phenotypic transformation, by which the tumor cells
gain the ability to proliferate against those suppression factors, the
suppression rate imposed by suppression factors on individual
tumor cells, and the mechanical rigidity of the microenvironment.
The growth dynamics influenced by these parameters include the
existence of a dormant period in tumor’s growth, the length of the
dormant period (if there exists one) and the existence of a sudden
‘‘switch’’ to a highly proliferative state. We also demonstrate that if
the number of actively dividing cells within the proliferative rim
reaches a critical, yet low level, the tumor has a high probability to
begin rapid proliferation. While we study a 2D CA model for
simplicity in this paper, our model can be easily generalized to
three dimensions (3D).
Figure 1. Fluorescence micrograph of a breast tumor stained to visualize carcinoma cells (phospho-p53, green) surrounded by
macrophages (CD11b, red) (a). Nuclei appear blue (DAPI). Image courtesy of Michael Graham Espey, PhD, National Cancer Institute, NIH (private
communication). (b) Representative pictures of dormant and fast-growing tumors and their vascular structure. Reprinted from Cancer Letters, 294,
Almog N, Molecular mechanisms underlying tumor dormancy, 139–146, Copyright (2010), with permission from Elsevier.
doi:10.1371/journal.pone.0109934.g001
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Materials and Methods
We divide the two-dimensional square simulation box into
different polygonal units (i.e., automaton cells). Our model is
coarse-grained, allowing us to grow the tumor from a very small
size with a cross section of roughly 1000 real cells through to a fully
developed tumor with a cross section consisting of 2.06106 cells.
Specifically, the innermost automaton cells represent roughly 100
real tumor cells or or a region of host microenvironment of similar
size, while the outermost automaton cells represent roughly 104
real tumor cells or a region of host microenvironment of similar
size. To generate the automaton cells in the simulation box, we
first fill the simulation box with non-overlapping circular disks (or
spheres in 3D) using random-sequential-addition packing method
[43] until there is no void space left for additional circular disks (or
spheres in 3D). Periodic boundary conditions are used for
generating the packing. Then we divide the simulation box into
polygons (or polyhedra in 3D), each polygon (or polyhedron in 3D)
associated with a particle center, such that any point within a
polygon (or polyhedron in 3D) [i.e., a Voronoi polygon (or
polyhedron in 3D)] is closer to its associated particle center than to
any other particle centers. The resulting Voronoi polygons (or
polyhedra in 3D) are referred to as automaton cells. In this paper,
we focus on the two-dimensional case, but our model should be
readily generalized to three dimensions.
The microenvironment surrounding a tumor is mainly com-
posed of stroma cells and extracellular matrix (ECM). In the
current model, we explicitly take into account the effects of the
ECM macromolecule density, ECM degradation by the prolifer-
ative cells, and the pressure built up due to the ECM deformation
by tumor growth. The effects of the stroma cells are not explicitly
considered in our current model. Henceforth, we will refer to the
regions of microenvironment as ECM-associated cells for simplic-
ity. In addition, we consider the interactions between the tumor
and the various suppression factors in the microenvironment, for
example the immune system. Since we consider development of
primary tumor or local recurrences of micrometastases under
microenvironmental suppression, invasive tumor growth is not a
mechanism relevant for our purposes and hence is not included in
our dormancy model.
In our model of noninvasive proliferative tumor growth, tumor
cells can be in one of the three possible states: proliferative,
quiescent or necrotic, depending on their nutrient supply.
Proliferative cells are tumor cells that have enough nutrients and
possess the ability to divide. Quiescent (or arrested) cells are tumor
cells that are alive, but do not have enough nutrient supply to
support cell division. Quiescent cells can eventually become inert,
necrotic (dead) cells due to an insufficient nutrient supply. In this
paper, we focus on avascular tumor growth and assume that there
is no explicit angiogenesis during the growth process (although this
assumption can be relaxed). The nutrients available to tumor cells
are those that diffuse into the tumor region through tumor edge.
As the tumor grows, the amount of nutrient supply, which is
proportional to the perimeter of the tumor interface (or surface
area of the tumor interface in 3D), cannot meet the needs of all of
the tumor cells. As a result, quiescent and necrotic regions emerge
near the center of the tumor. The state of a tumor cell is
determined by its distance to the tumor edge (i.e., the source of
nutrients). We assume that proliferative cells more than dp away
from the tumor edge become quiescent and quiescent cells more
than dn away from the tumor edge become necrotic (see details
below).
In this section, we will introduce our CA dormancy model,
which modifies our previous basic CA models of tumor growth
[41,42,44] by introducing several additional parameters to
incorporate the interactions between tumor cells and the
microenvironmental suppression factors. This dynamical model
is capable of producing situations in which a ‘‘switch’’ from a
dormant state to a proliferative state spontaneously emerges.
Noninvasive proliferative tumor growth
We now specify the cellular automaton rules used in our model
for noninvasive proliferative tumor growth. Each ECM-associated
automaton cell is assigned a specific density rECM, representing
the density of the ECM molecules within the automaton cell. If a
proliferative cell divides, its daughter cell occupies a nearby ECM-
associated cell. The daughter cell pushes away or degrades the
ECM within the ECM-associated cell it occupies. Initially, a tumor
is introduced by designating several automaton cells at the center
of the growth permitting region as proliferative tumor cells. Then
time is discretized into units, with each time step representing one
day. At each time step, the tumor grows according to the following
cellular automaton rules.
N Quiescent cells more than a certain distance dn from the
tumor’s edge are turned necrotic. The tumor’s edge, which is
assumed to be the source of nutrients, consists of all ECM-
associated cells that border the tumor. The critical distance dn
for quiescent cells to turn necrotic is computed as follows:
dn~aL
(d{1)=d
t , ð1Þ
where a is the necrotic thickness controlled by nutritional
needs, d is the Euclidean spatial dimension and Lt is the
distance between the geometric centroid xc of the tumor (i.e.,
xc~
PN
i xi=N, where N is the total number of cells in the
tumor) and the tumor edge cell that is closest to the quiescent
cell under consideration.
N Proliferative cells more than a certain distance dp from the tumor’s
edge are turned quiescent. The critical distance dp is given by
dp~bL
(d{1)=d
t , ð2Þ
where b is the proliferative thickness controlled by nutritional
needs, d is the spatial dimension and Lt is the distance between the
geometric tumor centroid xc and the tumor edge cell that is closest
to the proliferative cell under consideration.
N The probability of division for a proliferative cell used in our
model is
pdiv~p0½1{rECM{v(j{1)zj
‘
w
: ð3Þ
where p0 = 0.192 is the base probability of division linked to
cell-doubling time, rECM is the local ECM density,
v~2r0ECM is a parameter taking into account the effect of
pressure, j~rECM=r
0
ECM is the ratio of current average ECM
density over the initial density, and ‘ and w are, respectively,
the length and width of local protrusion tips.
Interactions between the tumor and the
microenvironmental suppression factors
Here, we specify the additional interaction rules between the
tumor and the microenvironmental suppression factors beyond the
aforementioned ones for noninvasive proliferative growth, which
were not included in our previous CA models. We assume that
there are two possible states of proliferative cells, dormant or
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actively dividing, depending on their interactions with the
microenvironmental suppression factors.
N Initially, we assume that all proliferative cells are kept in
dormant states by the microenvironmental suppression
factors, which means that they are not able to divide.
N At each day, beyond the aforementioned CA rules for
proliferative noninvasive growth, each dormant proliferative
cell has a certain probability c to change in their phenotypes
due to intracellular factors or external stimulus. The cell with
phenotype change gains different degrees of resistance to the
suppression factors in the microenvironment, depending on
the specific phenotype change the cell undergoes. For
example, mutated leukaemic cells in acute myeloid leukaemia
acquire resistance to cytotoxic T lymphocytes-mediated cell
lysis, whose degree is related to the level of the cell’s
expression of B7-H1 or B7.1 [45]. For simplicity, we divide
the phenotypic changes into two different types: weak changes
and strong changes with respect to their resistance to the
suppression factors in the microenvironment (i.e. their ability
to actively proliferate). Henceforth, we will refer to these
phenotypic changes as ‘‘transformations’’ and the cells that
undergo these changes as ‘‘transformed’’ cells for simplicity.
Strong-type ‘‘transformed’’ cells gain a larger competition
advantage and thus have a greater ability to divide actively.
The quantities xW and xS are the fractions of weak-type
‘‘transformations’’ and strong-type ‘‘transformations’’.
Henceforth, we set xW 0.99 and xS 0.01.
N At each subsequent day, the microenvironmental suppression
factors will counteract the weak-type ‘‘transformed’’ and
strong-type ‘‘transformed’’ cells with probabilities aW and aS.
The suppression factors in the microenvironment will either
kill the ‘‘transformed’’ cells or turn them back into dormant
cells [14,15].
N When the number of tumor cells reaches a certain threshold
NT, strong reactions of the microenvironmental factors are
triggered and those factors start to kill the ‘‘transformed’’ cells.
The parameter NT is introduced to ensure that the tumor is
not completely removed by the microenvironmental suppres-
sion factors. Note that the particular choice of NT barely has
any effect on the simulation results within a relatively wide
range of NT values. In this work NT is set to be 50, a
sufficiently small value that leads to biophysically realistic
outcomes. As the tumor grows, the microenvironmental
factors are weakened by the tumor, resulting in weaker
suppression of the tumor cells [46,47]. Therefore, when the
microenvironmental factors counteract the ‘‘transformed’’
cells, the fraction of the cells that are killed can be coupled
with the growth rate of the tumor by
k~k0(1{
1
DrC
dA
dt
): ð4Þ
where k0 is a constant characterizing the strength of the
suppression factors in the microenvironment, dA/dt is the
daily area change of the tumor (i.e. the growth rate of the
tumor), and DrC is the critical value of the tumor’s growth
rate. In this work, DrC is chosen as half of the tumor’s
maximum growth rate under suppression, but our numerical
tests have revealed that the simulation results are insensitive to
the choice of DrC as long as DrC is smaller than the tumor’s
maximum growth rate. When the growth rate of the tumor
reaches this critical value, the suppression factors become too
weak to kill any actively dividing tumor cells and k is set to be
0 [46,47].
N Due to the ‘‘competition’’ between the tumor and the
suppression factors in the microenvironment, the ratio of the
number of actively dividing proliferative cells over the total
number of proliferative cells n
pro
acti=n
pro changes with time. The
larger is this ratio n
pro
acti=n
pro, the larger is the amount of
nutrients the tumor tissue consumes. As a result, the nutrient
concentration around the tumor depends on the ratio
n
pro
acti=n
pro. Therefore, we make the necrotic thickness a and
proliferative thickness b functions of nproacti=n
pro:
a~a0½q{(q{1:0) n
pro
acti
npro
: ð5Þ
b~b0½s{(s{1:0) n
pro
acti
npro
: ð6Þ
where a0 = 0.58 mm
1/2 and b0 = 0.30 mm
1/2 are base
necrotic thickness and base proliferative thickness respective-
ly, q=1.6, s=2.0 are parameters determining the ranges of
necrotic thickness and proliferative thickness as n
pro
acti=n
pro
changes.
The aforementioned additional parameters associated with the
new rules that we employ for dormancy (beyond the ones for
noninvasive proliferative growth) are summarized in Table 1.
These parameters are sufficient to formulate a model in which the
transition from ‘‘dormant’’ to proliferative state emerges sponta-
neously. Note that unlike other parameters listed in Table 1, the
two critical threshold parameters themselves do not incorporate
any additional CA rules. Instead, the critical threshold parameters
determine when the microenvironmental suppression factors are
able to kill the proliferative cells. Also, it is noteworthy that we
map the complicated tumor-host interactions onto a number of
‘‘effective’’ parameters. The values of these parameters could differ
for different tumors in different microenvironments. It is
noteworthy that currently due to a lack of detailed in-vivo or in-
vitro data for the growth dynamics of a dormant tumor, we are not
able to determine the values of the parameters in our model for a
specific real system. Instead, we have done a full parametric study
to probe different outcomes corresponding to different parameter
values in the subsequent sections. However, once we obtain the
statistics of a dormant tumor as a function of time from the
initiation of the tumor, we should be able to extract the parameter
values for the tumor by fitting the statistics. At this stage, the
extracted parameter values could be applied to other tumors of
similar type.
Noninvasive proliferative tumor growth under
suppression
Here, we specify how the additional interaction rules are
coupled together with the original CA rules for noninvasive
proliferative tumor growth, resulting in noninvasive proliferative
tumor growth under suppression.
N As mentioned above, proliferative cells in the dormant state do
not divide. Only proliferative cells in actively dividing states
actually proliferate.
N At each day, each dormant proliferate cell is checked to see if it
enters the active state according to the interaction rules. Once
it begins to actively divide, it proliferates according to the CA
rules for proliferative tumor growth.
N At each day, each active proliferative cell is checked to see if it
is killed or turned back into dormant cell according to the
interaction rules.
Modeling Tumor Dormancy with an Emergent Switch Behavior
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N Quiescent cells and necrotic cells act according to CA rules for
proliferative tumor growth. However, the values of parameters
a and b determining the transitions from necrotic cells to
quiescent cells and from proliferative cells to quiescent cells
respectively are influenced by interaction rules, as mentioned
above.
Note that our CA dormancy model should be readily
generalized to angiogenic dormancy by explicitly considering the
angiogenic process and vascular tumor growth. This is beyond the
scope of this work and will be addressed in future work.
Results
In this section, we apply our CA model and show that it
produces a dormancy period of the tumor that can lead to a
subsequent emergent ‘‘switch’’ behavior to a proliferative state. A
homogeneous distribution of ECM density is used for simplicity
[41]. A circular growth permitting region containing ,26104
automaton cells is employed. Simulating the growth of a 2D tumor
from several cells (representing roughly 1000 real cells) to a
macroscopic-size tumor (a cross section of 5 cm2 consisting of
,26106 real cells) with a period of dormancy up to a person’s life
(,80 years) generally takes no more than a few minutes on a
standard Dell Workstation (Precision T3400).
Initially, a few automaton cells at the center of the growth-
permitting region are designated as proliferative cells. Then the
initial tumor is allowed to grow according to our CA model
incorporating the additional interaction rules between the tumor
and the suppression factors in the microenvironment. Certain
geometrical characteristics of the tumor (e.g., tumor area, areas of
different tumor cell populations) and its morphology (e.g., the
geometrical positions of the tumor cells) are collected every Tc
days. We set c~0:005, aW=0.75, aS=0.15, k0 = 0.8 and use these
parameter values throughout this paper, except where otherwise
stated.
Statistics of tumor growth
Here we consider the growth of a proliferative tumor in a
confined space with rECM~0:30. As shown in Figure 2(a), with
the interactions between the tumor and the microenvironmental
suppression factors incorporated, there exists a period of
dormancy in the tumor’s growth. Specifically, for the initial
approximate 900 days, the tumor stays in a dormant state.
Suddenly at approximately day 900, the tumor switches its
behavior and begins rapid proliferation. The virtual patient would
die 100 days after this critical point in time. Figure 2(b) shows the
areas A of different populations normalized by the area of the
growth-permitting area A0. For purposes of comparison, Fig-
ure 2(c) and Figure 2(d) show the statistics of the tumor growth
without the suppression of microenvironmental factors. Moreover,
by comparing Figure 2(a) and Figure 2(c), it is seen that the
interactions between the tumor and the microenvironmental
suppression factors lead to the existence of a dormancy period and
a subsequent emergent ‘‘switch’’ behavior of the tumor from a
dormant state to a proliferative state. Also, from the comparison of
Figure 2(b) and Figure 2(d), one can see that the additional
interaction rules alter the fractions of necrotic cell population and
proliferative cell population within the tumor. When suppression
of the tumor growth is present, the necrotic region decreases and
the proliferative region increases relatively; the area of the
quiescent region remains almost unchanged.
Figure 3 shows snapshots of the simulated 2D tumor. It can be
clearly seen that the tumor develops a highly aspherical
morphology due to the interactions between the tumor and the
microenvironmental factors. Figure 3 also demonstrates that the
tumor hardly grows during the period of dormancy, but once the
‘‘switch’’ occurs, the tumor expands very rapidly. Henceforth, we
will use the ‘‘CA dormancy model’’ to investigate the effects of the
various parameters characterizing the tumor-host interactions on
the growth dynamics of the tumor. These parameters include the
rate of phenotypic transformation, by which the tumor cells gain
the ability to proliferate against those suppression factors, the
suppression rate imposed by suppression factors on individual
tumor cells, and the mechanical rigidity of the microenvironment.
Suppression rate vs transformation rate
Here we investigate growth dynamics of the tumor under
different suppression rates a and phenotypic transformation rates
c. The suppression rate a is defined as the following weighted
average:
a~aW :xWzaS:xS: ð7Þ
where xW=0.99 and xS=0.01 are the fractions of weak-type
Table 1. Parameters characterizing the interactions between tumor suppression factors and tumor cells in the CA dormancy
model.
Tumor growth parameters
c Probability of phenotypic change for a dormant proliferative cell to acquire the dividing ability
xW Fraction of weak-type transformations
xS Fraction of strong-type transformations
Microenvironmental suppression parameters
aW Probability that suppression factors counteract the weak-type transformed cell at each day
aS Probability that suppression factors counteract the strong-type transformed cell at each day
k Fraction of ‘‘transformed’’ cells killed when suppression factors counteract the ‘‘transformed’’ cells (time dependent)
Critical threshold values
NT Critical value of proliferative tumor cell number, beyond which suppression of tumor growth is triggered
DrC Critical value of tumor growth rate, beyond which the suppression factors are unable to kill the ‘‘transformed’’ cells
Note that the two ‘‘critical threshold’’ parameters themselves do not incorporate any additional CA rules.
doi:10.1371/journal.pone.0109934.t001
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‘‘transformations’’ and strong-type ‘‘transformations’’, and aW and
aS are the suppression rates of the weak-type ‘‘transformed’’ cells
and strong-type ‘‘transformed’’ cells by the microenvironmental
factors. It is found that increasing a and decreasing c generally
increases the length of the dormancy period and delays the
‘‘switch’’ from a dormant state to a proliferative state, as
demonstrated in Figure 4(a). Within some regimes of a and c,
the tumor could lie dormant for a period equal to or longer than a
person’s life (,80 years).
Based on our simulation results, we construct a ‘‘phase
diagram’’ to characterize the tumor’s growth dynamics in terms
of a and c, as shown in Figure 4(b). There are two regions in this
phase diagram: proliferative and dormant regions. By ‘‘prolifer-
ative’’, we mean that the tumor resumes rapid proliferation after a
period of dormancy and the length of the dormancy period is less
than a virtual patient’s life; by ‘‘dormant’’, we mean that the tumor
remains in a dormant state during the whole life of a person and
undetected by conventional clinical methods (usually clinicians call
such tumors ‘‘benign’’ [48–50]). The solid line separates the two
regions, and crossing this boundary line is associated with a ‘‘phase
transition’’.
Rigidity of the microenvironment
Various mechanical cues in the microenvironment could
influence the growth dynamics of the tumor [51]. Here we only
consider the effects of the ECM macromolecule density, ECM
degradation by the proliferative cells, and the pressure built up due
to the ECM deformation by tumor growth. As shown in Figure 5,
when ECM rigidity increases, the time at which the switch occurs
gets delayed significantly and the final size of the tumor when it
plateaus appreciably decreases. For example, with all the other
parameters fixed, when the tumor grows in a soft ECM with
rECM~0:15, the ‘‘switch’’ point occurs approximately on day 250.
This is to be contrasted with growth in a rigid ECM with
rECM~0:45 where the dormancy period could last for 2,000 days
before a ‘‘switch’’ to a proliferative state occurs. Also, the plateau
size of the tumor growing in a soft ECM with rECM~0:15 is five
times as large as that of one growing in a rigid ECM with
rECM~0:45. In other words, when the tumor grows in a harsher
microenvironment, it’s harder for the tumor to break out of a
dormant state and potential proliferative growth is largely
suppressed. Note that the rigidity of the microenvironment could
also affect tumor growth via various intracellular signaling
Figure 2. Upper panel: statistics of a simulated noninvasive tumor growing in the ECM with rECM~0:3 and microenvironmental
suppression factors, as predicted by the ‘‘CA dormancy model’’. (a) Tumor area AT normalized by the area A0 of the growth permitting
region. (b) Areas of different cell populations normalized by the area A0 of the growth permitting region. Lower panel: statistics of a simulated
noninvasive tumor growing in the ECM with rECM~0:3 without suppression. (c) Tumor area AT normalized by the area A0 of the growth permitting
region. (d) Areas of different cell populations normalized by the area A0 of the growth permitting region.
doi:10.1371/journal.pone.0109934.g002
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processes [51]. Those mechanotransduction effects will be
incorporated into our CA dormancy model in future work, which
could result in different scenarios from those reported here [51].
Strength of the suppression factors
Here we investigate how tumor growth dynamics changes with
the strength of the microenvironmental suppression factors. As
shown in Figure 6, increasing the fraction of actively dividing
tumor cells that are killed [i.e., increasing k0 in the equation (4)]
when the microenvironmental suppression factors (which we recall
could either kill the ‘‘transformed’’ cells or turn them back into
dormant cells) delays the ‘‘switch’’ point from a dormant state to a
rapid proliferative state and decreases the final tumor size.
However, relatively speaking, the simulated tumor growth statistics
are insensitive to k0 compared to the influences of the aforemen-
tioned other factors. Note that even when the suppression factors
can only turn the ‘‘transformed’’ cells back into dormant cells and
do not kill any ‘‘transformed’’ cells (i.e. k0 = 0), a ‘‘switch’’ behavior
from a dormant state to a rapid proliferative state can still emerge.
This indicates that turning the active proliferative cells back into
dormant cells could also be a possible independent mechanism
leading to a dormancy period and a subsequent ‘‘switch’’ to a
proliferative state.
Discussion
In this paper, we generalized a two-dimensional cellular
automaton (CA) model previously developed for proliferative
growth of avascular solid tumors to investigate tumor dormancy
and evasion from dormancy to proliferation. Our CA dormancy
model incorporates a variety of cell-level tumor-host interactions,
including those between the tumor and the suppression factors in
the microenvironment, for example the immune system. Our CA
dormancy model induces a ‘‘competition’’ between the tumor’s
propensity to proliferate and the microenvironmental factors that
suppress its growth. Our CA dormancy model predicts a dramatic
emergent ‘‘switch’’ behavior from a dormant state to a rapidly
proliferative state. Our results show that under the suppression of
microenvironmental factors, the tumor develops a highly aspher-
ical morphology with an larger proliferative region and a smaller
necrotic region than those of a tumor that grows without the
presence of suppression factors. We also predict that if the number
of actively dividing cells within the proliferative rim of tumor
Figure 3. Snapshots of a simulated noninvasive tumor growing in the ECM with rECM~0:3 on different days given by the CA
dormancy model. Upper panel: Dormancy period. Lower panel: Regrowth period.
doi:10.1371/journal.pone.0109934.g003
Figure 4. The ‘‘critical’’ point at which the noninvasive tumor growing in the ECMwith rECM~0:3 switches from a dormant state to a
proliferative state as functions of a and ª (a). A schematic phase diagram that characterizes the growth dynamics of a noninvasive tumor
growing in the ECM with rECM~0:3 under different a and c (b).
doi:10.1371/journal.pone.0109934.g004
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reaches a critical, yet low level, the tumor has a large probability to
resume rapid regrowth and exit dormancy. In addition, we
demonstrate that a variety of different factors could greatly alter
tumor growth dynamics, including the rate of phenotypic
transformations, the suppression rate by the microenvironmental
factors, the mechanical rigidity of the microenvironment, and the
strength of the suppression factors. However, relatively speaking,
the tumor growth is insensitive to the strength of the suppression
factors in terms of killing active proliferative cells. We inferred
from our simulation results a qualitative phase diagram to
characterize the growth dynamics of the tumor under the
suppression of microenvironmental factors in terms of the
phenotypic transformation rate and the suppression rate. In this
paper we focused on the two-dimensional case, but our model
should be easily generalized to three dimensions.
At the cellular level, the origin of the ‘‘stalemate’’ between the
tumor and microenvironmental suppression factors remains
unclear. This ‘‘stalemate’’ may come from cell proliferation
balanced by cell death, which could be the case for a dividing
cancer stem cell [52]. Arrested tumor cell proliferation imposed by
microenvironmental factors could also result in the ‘‘stalemate’’
between the tumor and the microenvironmental suppression
factors. Both scenarios could account for the case of differentiated
cancer cells, since our CA dormancy model is coarse-grained and
therefore considers the effective behavior of the tumor.
Our CA dormancy model may shed light on the fundamental
understanding of cancer dormancy phenomenon. Specifically, our
CA dormancy model proposes possible scenarios for cancer
dormancy that during the dormancy period the great majority of
proliferative cells stay in a dormant state, while only a small
portion of proliferative cells, i.e., ‘‘transformed’’ cells are actively
dividing, and the microenvironmental suppression factors coun-
teract these ‘‘transformed’’ cells by either killing them or turning
them back into dormant cells. As a result, the tumor cell
population is barely expanding during the dormancy period. It
is noteworthy that our CA dormancy model predicts that the
tumor either eventually spontaneously emerges or is eradicated
after a period of a ‘‘stalemate’’ between the tumor and the
microenvironmental suppression factors; or the tumor is eradicat-
ed before such a ‘‘stalemate’’ could ever develop. These predicted
scenarios arising from the interaction between the tumor and the
microenvironmental suppression factors in our simulation quali-
tatively match the experimental observations of the cancer
immunoediting process, by which the immune system controls
the tumor growth and necessarily leads to tumor escape or
elimination [53]. The predictions of our CA dormancy model can
be further verified by comparing the macroscopic geometrical and
dynamical properties of our simulated tumor in different
microenvironments [54] to those obtained by experimental data
from future animal studies. In future work we plan on
incorporating recently discovered mechanisms for cancer dor-
mancy via the clinical trials and experiments [55,56] to better
inform our computational model. These results together could aid
in answering the important fundamental question of whether the
majority of cancer cells in a dormant tumor are arrested at a
certain stage of the cell cycle or not. Furthermore, they will have
significant treatment implications in terms of what stage of the cell
cycle the therapies should target [57].
Besides the aforementioned influences, our findings informed by
clinical data might be able to provide further insights to novel early
cancer detection and therapy. For example, a new cancer drug
that suppresses the emission of CD47 by the tumor tissues, which
helps the tumor cells evade attack by the immune system, has been
discovered [58]. It was shown via in vitro experiments that this
drug is able to kill a variety of cancer cell types. Thus, an effective
clinical application of this drug depends upon the ability to identify
different tumor cell populations while they are dormant. Our work
may serve to provide insights to the application of this new drug as
well by contributing to the development of new early detection
methods. In addition, our work may shed light on why the
immune system may not always be able to prevent tumor
progression. Specifically, our work shows that even if the immune
system maintains its strength throughout the tumor growth
process, there is still a high possibility that the immune system
could eventually fail, which is to be contrasted with the simple
explanations that it becomes weaker as the tumor develops [15–
18]. Also, for a tumor of a specific type, we can extract the
parameter values in our model by fitting our simulation results to
the statistics of a real in-vitro or in-vivo tumor of this type. Then
we can utilize our model to explore optimal treatment strategies
Figure 5. Simulated tumor area AT normalized by the area A0 of
the growth permitting region of a noninvasive tumor growing
in the ECM with different rECM.
doi:10.1371/journal.pone.0109934.g005
Figure 6. Tumor area AT normalized by the area A0 of the
growth permitting region of a simulated noninvasive tumor
growing in the ECM under different killing rates by microen-
vironmental suppression factors. The parameter k0 is the fraction
that the suppression factors from the microenvironment kill the actively
dividing proliferative cells when the suppression factors counteract
these cells.
doi:10.1371/journal.pone.0109934.g006
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for the tumors of this specific type. In addition, once we determine
the effects of a specific microenvironmental factor (e.g., specific
integrins [59]) on the parameter values in our model, we could
then study the effects of this microenvironmental factor on the
tumor growth dynamics.
Our current CA dormancy model is still preliminary, and to
achieve our ultimate goal of understanding cancer dormancy and
progression, we need to develop robust models that incorporate
appropriate cell-level tumor-host interactions that are informed by
experiments. For example, by explicitly considering angiogenesis
and using more realistic distribution of ‘‘transformed’’ tumor cells’
resistance to microenvironmental suppression factors (currently we
just divide the ‘‘transformed’’ cells into two types with respect to
their resistance to microenvironmental suppression factors: weak
and strong), our model might be able to yield more realistic results
and improve our understanding of cancer dormancy and
progression. Also, the effects of tumor cell competition, cooper-
ation and the microenvironmental changes caused by tumor cell
activities could be incorporated to further strengthen our CA
dormancy model [60]. It is noteworthy that although we employ
interaction rules based on a discrete cell model to describe
‘‘competition’’ between the tumor and the microenvironmental
suppression factors, alternatives such as evolutionary game theory
implemented by partial-differential equations are also available to
address the interplay between the tumor and the microenviron-
ment [61].
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